Compare FSTR & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FSTR | CCCC |
|---|---|---|
| Founded | 1902 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 442.3M | 404.7M |
| IPO Year | 1995 | 2020 |
| Metric | FSTR | CCCC |
|---|---|---|
| Price | $37.35 | $3.30 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $32.00 | $12.20 |
| AVG Volume (30 Days) | 31.4K | ★ 1.8M |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.45 |
| EPS | ★ 0.44 | N/A |
| Revenue | ★ $540,009,000.00 | $35,947,000.00 |
| Revenue This Year | $5.12 | N/A |
| Revenue Next Year | $2.78 | N/A |
| P/E Ratio | $85.40 | ★ N/A |
| Revenue Growth | ★ 1.74 | 1.02 |
| 52 Week Low | $24.30 | $1.69 |
| 52 Week High | $45.81 | $5.17 |
| Indicator | FSTR | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 44.16 | 34.31 |
| Support Level | $36.53 | $2.52 |
| Resistance Level | $38.68 | $3.91 |
| Average True Range (ATR) | 0.84 | 0.17 |
| MACD | 0.14 | -0.04 |
| Stochastic Oscillator | 57.45 | 7.27 |
L.B. Foster Co is a technology solutions provider of products and services for the rail and infrastructure markets. The company has two reporting segments: Rail, Technologies, and Services (Rail); and Infrastructure Solutions (Infrastructure). Maximum revenue is generated from the Rail segment, which is comprised of several manufacturing and distribution businesses that provide products and services for freight and passenger railroads and industrial companies throughout the world. The Infrastructure segment offers engineered precast concrete solutions, as well as fabricated bridge, protective pipe coating, and pipe threading offerings across North America. Geographically, the company generates maximum revenue from the United States, followed by Canada, the UK, and other markets.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.